| Position | Action |
|---|---|
| 75% of benchmark weight | Underweight target maintained; no active trim today |
| Total defensive budget 1-2% of portfolio | Hedge cost inclusive |
| Trim 15-20% of exposure | On Trigger #1 (confirmed close below $297 on volume ≥50M) or Trigger #2 (Q3 confirms FCF/margin decay) |
| Skip-trim override | If price reclaims 10 EMA ($325) on volume ≥50M with MACD histogram contracting |
TSLA's 35% drawdown has priced in all bearish narratives, creating an asymmetric risk/reward entry with the stock at a technical bottom, fortress balance sheet, and massive upside optionality from AI/robotics that the market isn't pricing.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 384.96 | bearish |
| close_200_sma | 409.99 | bearish |
| close_10_ema | 325.82 | neutral |
| rsi | 37.53 | neutral |
| macd | -22.25 | bearish |
| macds | -20.95 | bearish |
| macdh | -1.30 | bearish |
| boll | 351.64 | bearish |
| boll_ub | 432.11 | — |
| boll_lb | 271.17 | bullish |
| atr | 15.44 | — |
| vwma | ~328.85 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Underweight via hedge, not trim; defer reduction to catalyst or breakdown triggers
Underweight rating maintained (75% benchmark weight); hedge structure executed (Buy $280/Sell $240 put spread, 3-4 month tenor) for tail-risk definition; all active trims deferred until confirmed close below $297 or Q3 catalyst validation; hard stop on residual long at $285.
When: Q3 deliveries or Q3 earnings confirm FCF/margin decay (second consecutive negative FCF quarter AND operating margin below 2%)
Then: Trim additional 15-20%
CapEx surge is strategic investment, not deterioration
· concedes: TSLA is below 50 SMA and 200 SMA; MACD is negative; Q2 2026 FCF flipped negative; Death-cross structure exists; Operating margin compressed to 1.41%; Net income dropped from $15B (2023) to $3.8B (2025); Premium valuation at 145x P/E
TSLA at $321.55 is a value trap with deteriorating fundamentals, extreme valuation (145x forward P/E), and confirmed technical downtrend that hasn't fully priced in forward FCF deterioration, competitive robotaxi risk, and macro headwinds.
→ vs conservative: Fortress balance sheet argument ignores that $27 billion net cash is a countdown timer when operating margin is 1.41% and FCF is negative $1.10 billion - every quarter without margin expansion shrinks optionality
→ vs conservative: 145x forward P/E with 4.72 PEG ratio prices in perfection while actual execution shows margin collapse, making long-term hold at these levels denial rather than conviction
→ vs neutral: 'Wait for confirmation' after a 35% drawdown means waiting for a dead cat bounce before the next leg down; the 10 EMA at 325 already acted as resistance not support
→ vs neutral: RSI at 37 not being oversold is used as a reason to wait, but waiting for full confirmation means missing the asymmetric entry opportunity at 271 or 298
Support: 271.17 · 298.32 · 311.21 | Resistance: 325.82 · 328.85 · 351.64 · 384.96 · 409.99 · 432.11
TSLA exhibits a strongly bearish structural trend with price 18% below the 50 SMA and 27.4% below the 200 SMA, confirming a death-cross posture. Short-term, a bottoming bounce attempt is underway after the July 23 capitulation gap-down, with price testing the 10 EMA at 325.82 as the critical near-term trigger level. Momentum indicators show bearish dominance (MACD below signal line at -22.25 vs -20.95, histogram -1.30) but potentially exhausting, while RSI at 37.53 sits in the lower half without reaching oversold territory. Volume has declined to 27.5M from the 115.6M spike on the breakdown, suggesting selling pressure is waning. The VWMA at ~328.85 sits above price, confirming lack of institutional volume participation in the bounce. ATR of 15.44 suggests $15-30 stops for tactical trades. Recommendation is HOLD — existing holders should tighten stops, tactical traders should wait for bullish MACD crossover AND daily close above 10 EMA (325.82) with RSI rising through 40-50 and VWMA curling higher before initiating counter-trend longs.
Market Cap
$1,269.98 B
Trailing P/E
297.7x
Forward P/E
144.9x
PEG Ratio
4.72
P/B
14.62x
EPS (TTM)
$1.08
Forward EPS
$2.22
Beta
1.83
52-Week High
$498.83
52-Week Low
$297.38
50-Day Avg
$388.86
200-Day Avg
$411.06
Revenue (TTM)
$103.6 B
Revenue FY2025
$94.8 B
Gross Margin (TTM)
~18.8%
Operating Margin
1.41%
Net Margin
3.67%
ROE
4.67%
ROA
1.93%
Cash & ST Investments
$43.5 B
Total Debt
$16.1 B
Net Cash
~$27 B
Stockholders' Equity
$86.9 B
Current Ratio
1.94
Operating CF (TTM)
~$18.7 B
Free Cash Flow (TTM)
$4.84 B
CapEx Q2 2026
$5.80 B
Q2 2026 Free Cash Flow
-$1.10 B
FCF FY2025
$6.2 B
Net Income FY2023
$15.0 B
Net Income FY2024
$7.1 B
Net Income FY2025
$3.8 B
Diluted EPS FY2023
$4.31
Diluted EPS FY2024
$2.04
Diluted EPS FY2025
$1.08
Q2 2026 Revenue
$28.24 B
Q2 2026 Net Income
$1.11 B
Q2 2026 Diluted EPS
$0.32
Q2 2026 Operating Income
$0.40 B
Q2 2026 R&D
$2.37 B
Stock-Based Compensation
~$2.8 B/yr
Share Count Q2 2026
3.95 B
Net PPE
$62.4 B
Strengths
Concerns
Tesla presents a high-risk, high-reward profile where the market is paying for a 2027+ AI/autonomy story rather than current fundamentals. The fortress balance sheet ($27B net cash) provides resilience through an aggressive investment cycle, but the fundamental picture shows net income declining ~75% from 2023 ($15.0B) to 2025 ($3.8B) as R&D and CapEx ramp significantly. Q2 2026 marked a turning point with negative FCF (-$1.1B) as CapEx nearly doubled to $5.8B, and operating margin compressed to just 1.41% despite record quarterly revenue of $28.24B. The valuation is priced for perfection — Forward P/E of 145x is only justified if FSD/Robotaxi/Optimus deliver, making this a story-driven rather than valuation-driven trade at present levels.